LifeMine Therapeutics is upending the standard paradigm for drug discovery by mining the biosphere to discover disruptively innovative drugs. The biotech company has built a first-of-its-kind genomically-enabled drug discovery platform that can rapidly develop new drugs from fungi. Co-founded in 2017 by academic scientist, biotech entrepreneur, investor, and chief executive Gregory Verdine, LifeMine aims to develop drugs for previously untreatable and significant chronic diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/18/17 | $55,000,000 | Series A |
Alexandria Real Estate Equities ARCH Venture Partners Blue Pool Capital Boyu Capital Foresite Capital Merck Ventures WuXi Healthcare Ventures  | undisclosed |
| 03/23/22 | $175,000,000 | Series C |
3W Partners Capital ARCH Venture Partners Blue Pool Capital Fidelity Management & Research Company GlaxoSmithKline GV Invus MRL Ventures Fund | undisclosed |
